Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP5 | Q01469 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CASP3 | P42574 | 3/20 | 0.37 |
| ▸ | FABP7 | O15540 | 2/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | MMP14 | P50281 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9355864 | 0.93 | FABP5 (0.39) | FABP5CA1CA2KMT2ACASP3 | |
| SCHEMBL9647974 | 0.92 | KMT2A (0.43) | FABP5CA1CA2KMT2ACASP3 | |
| Trifluoromethanesulfonic Acid SCHEMBL9323678 | 0.81 | CA1 (0.38) | FABP5CA1CA2KMT2ACASP3 | |
| Methylsulfanylmethane SCHEMBL8351795 | 0.81 | FABP5 (0.39) | FABP5CA1CA2KMT2ACASP3 | |
| SCHEMBL8517516 | 0.79 | KMT2A (0.43) | FABP5CA1CA2KMT2AFABP7 | |
| SCHEMBL4807073 | 0.78 | CA1 (0.46) | FABP5CA1CA2KMT2ACASP3 | |
| SCHEMBL27143076 | 0.78 | FABP5 (0.52) | FABP5CA1CA2KMT2ACASP3 | |
| SCHEMBL9355666 | 0.77 | KMT2A (0.43) | FABP5CA1CA2KMT2ACASP3 | |
| SCHEMBL14099780 | 0.76 | CYP1A2 (0.47) | FABP5KMT2AFABP7EPHX2 | |
| SCHEMBL9225108 | 0.75 | GAA (0.49) | FABP5KMT2AFABP7EPHX2MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076294-B2 | Collagen-related peptides and uses thereof | ADVANCED TECHNOLOGIES AND REGENERATIVE MEDICINE, LLC. (US) | 2011-12-13 | — | — | US | disclosed |
| EP-2391393-A2 | PCL/PGA HEMOSTATIC FOAMS | Ethicon, Inc (US) | 2011-12-07 | — | — | EP | disclosed |
| EP-2183280-B1 | COLLAGEN-RELATED PEPTIDES AND USES THEREOF | ETHICON INC (US) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010088469-A2 | COLLAGEN-RELATED PEPTIDES AND USES THEREOF AND HEMOSTATIC FOAM SUBSTRATES | ETHICON, INC. (US) | 2010-08-05 | — | — | WO | disclosed |
| EP-2183280-A2 | COLLAGEN-RELATED PEPTIDES AND USES THEREOF | ETHICON, INC. (US) | 2010-05-12 | — | — | EP | disclosed |
| US-20100021527-A1 | COLLAGEN-RELATED PEPTIDES AND USES THEREOF AND HEMOSTATIC FOAM SUBSTRATES | ETHICON, INC. | 2010-01-28 | — | — | US | disclosed |
| US-20090299034-A1 | Collagen-related peptides | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-12-03 | — | — | US | disclosed |
| US-20090068246-A1 | COLLAGEN-RELATED PEPTIDES AND USES THEREOF | ETHICON, INC. | 2009-03-12 | — | — | US | disclosed |
| WO-2009018126-A2 | COLLAGEN-RELATED PEPTIDES AND USES THEREOF | ETHICON, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009017482-A1 | COLLAGEN-RELATED PEPTIDES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-02-05 | — | — | WO | disclosed |
| EP-1019089-B1 | LONG-ACTING DRUGS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | YEDA RES & DEV (IL) | 2005-11-09 | — | — | EP | disclosed |
| US-6504005-B1 | Conjugates of a polypeptide or oligopeptide with a low molecular weight lipophilic compound, the peptide and lipophilic group being covalently linked to one another either directly or via a connecting element, with the exception of | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2003-01-07 | — | — | US | disclosed |
| US-6096863-A | PEPTIDE COMPLEX WITH A LINKED LIPOPHILIC PORTION; FOR DRUG DELIVERY DEVICES FOR TARGETED CELLS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2000-08-01 | — | — | US | disclosed |
| WO-1999020300-A1 | INHIBITION OF TUMOR CELL ADHESION TO TYPE IV COLLAGEN | THE REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1999-04-29 | — | — | WO | disclosed |
| US-5853744-A | Solid-phase method for attaching a biomolecule to a substrate surface with a photoreactive crosslinking agent | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1998-12-29 | — | — | US | disclosed |
| US-4990644-A | Water solubility | SANSHIN KAGAKU KOGYO CO. LTD. (JP) | 1991-02-05 | — | — | US | disclosed |
| EP-0331988-A1 | Sulfonium compounds, as well as process for producing active esters and amides used for the production of amides | SANSHIN KAGAKU KOGYO CO., LTD. (JP) | 1989-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090299034-A1 | Collagen-related peptides | COL14A1, COL2A1, COL1A1 | FABP5 450/4885CA1 955/4885CA2 2273/4885 |
| US-20100021527-A1 | COLLAGEN-RELATED PEPTIDES AND USES THEREOF AND HEMOSTATIC FOAM SUBSTRATES | FGB, F2, F13B | FABP5 291/4885CA1 2188/4885CA2 3229/4885 |
| US-20090068246-A1 | COLLAGEN-RELATED PEPTIDES AND USES THEREOF | COL14A1, COL2A1, COL1A1 | FABP5 559/4885CA1 832/4885CA2 2169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.